Storebrand Asset Management AS
Lysaker, 15 January 2021
Financial Calender 2021
Fund name and share class | Symbol | ISIN |
Storebrand Indeks – Alle Markeder A5 | STIIAM | NO0010841588 |
Storebrand Indeks – Nye Markeder A5 | STIINM | NO0010841570 |
Storebrand Global ESG Plus A5 | STIGEP | NO0010841604 |
Storebrand Global Solutions A5 | STIGS | NO0010841612 |
Storebrand Global Multifactor A5 | STIGM | NO0010841596 |
FINANCIAL YEAR 2020
23.04.2021 – Annual Report
FINANCIAL YEAR 2021
24.03.2021 – Election meeting
13.07.2021 – Semi annual Report
29.04.2022 – Annual Report
The funds listed on Nasdaq Copenhagen will be available for trading during the Nasdaq opening hours. Jyske Bank is acting as the market maker, and will ensure transferability for the funds.
For queries, you may contact Storebrand's Danish branch on +45 33 41 76 53, or Kim.Toftegaard.Andreassen@storebrand.com
Regards
Storebrand Asset Management AS
Contacts:
Kim Toftegaard Andreassen, Director, +45 33 41 76 53
Frode Aasen, Product Manager, +47 934 03 934
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
FLSmidth A/S9.7.2025 08:41:33 CEST | Press release
Correction to Company Announcement no. 15-2025: Transactions under share buy-back programme
Syensqo SA9.7.2025 08:30:00 CEST | Press release
Syensqo - Participation notification by BlackRock Inc.
Sparekassen Sjælland-Fyn A/S9.7.2025 08:13:26 CEST | Pressemeddelelse
SJF Bank opjusterer forventningerne til resultatet for 2025
Ekopak N.V.9.7.2025 08:10:24 CEST | Press release
Ekopak appoints Jean-Baptiste De Cuyper as new CEO
Purespring Therapeutics9.7.2025 08:00:00 CEST | Press release
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom